Navigation Links
Cardiome And Astellas Announce Regulatory Update
Date:1/21/2008

or the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities.

In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at '/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Hold Investor Update Call
2. Cardiome Updates Guidance
3. Cardiome Initiates Phase 1 Study for GED-aPC
4. Cardiome To Release Third Quarter Results
5. Cardiome to Present at CIBC Conference
6. Cardiome to Present at ThinkEquity Conference
7. Cardiome to Present at Bear Stearns Conference
8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
9. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
10. Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer
11. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... By Steven Reinberg ... -- A device intended to help with weight loss by ... to meet expectations in a trial among obese patients. ... between the brain and stomach, researchers hoped to suppress feelings ... they anticipated. "A device that safely blocks the nerve ...
(Date:9/2/2014)... ANGELES (Sept. 2, 2014) Measuring the levels of sex ... a sudden cardiac arrest, a heart rhythm disorder that is ... study, published online by the peer-reviewed journal Heart Rhythm ... sex hormone, were found in men who had a sudden ... hormone, were strongly associated with greater chances of having a ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Evolve ... within the primary and urgent care arena, is ... opening coincides with a health fair the clinic ... incorporating technology to assist patients in achieving high ... Medical Clinics’ pricing structure is a groundbreaking change ...
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... soccer tickets. The first week in September will be ... Teams from Brazil, Colombia, Mexico, Chile, Ecuador and Bolivia ... The following matches will take place between September 5th - ... Stadium on Tuesday, September 9th , Mexico vs. ...
(Date:9/2/2014)... your outpatient doctor does not know? Or when ... but your doctor does not have the right ... incomplete communication from hospitals to outpatient primary care ... lead to hospital readmissions. , However, a ... hospitals, communication during patient care transitions. Researchers from ...
Breaking Medicine News(10 mins):Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Study links sex hormone levels in the blood to risk of sudden cardiac arrest 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Can data motivate hospital leaders to improve care transitions? 2
... Integrated Medical,Systems, Inc., a medical technology systems integrator ... that it has received,510(k) clearance from the U.S. ... 1000(TM) "suitcase" intensive care unit (ICU)., "FDA ... accomplishment for the,company as we continue to demonstrate ...
... PhD.,co-founder and Chief Scientific Officer of Posit Science, has ... announcement by the Institute,today. Dr. Merzenich is one of ... a highly selective process that recognizes,people who have made ... care, and public health. Election is considered one of ...
... Oct. 13 The 2008 NCPA Digest,sponsored by ... 110th Annual,Convention. The Digest has been published annually ... portrait of the financial state of,independent community pharmacy ... an inside look into how the Medicare Part ...
... Knowledge Sharing among Physicians, MOUNTAIN VIEW, Calif., ... the healthcare IT market, Frost & Sullivan recognizes,Infor-Med, ... Sullivan Award for,Technology Innovation for its novel Praxis(R) ... EMR Knowledge Exchanger., The Praxis(R) EMR system ...
... 13 NeoVista, Inc., presented,yesterday the anatomic ... on choroidal neovascular lesions in an analysis ... 26th Annual Meeting. The,12-month data presented by ... Houston, Texas, demonstrated anatomic improvements on both,angiography ...
... neonatology fellows have been awarded grants designed to ... follow-up care of the premature infant as part ... MedImmune,s commitment to expanding research within pediatric medicine, ... totaling $175,000 in research funding. The five recipients ...
Cached Medicine News:Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3Health News:Merzenich Elected to Institute of Medicine 2Health News:Merzenich Elected to Institute of Medicine 3Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 2Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 3Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com announces ... its catalogue: Asia - Pacific Minimally ... http://www.reportlinker.com/p02353212/Asia---Pacific-Minimally-Invasive-Surgery-Spinal-Device-Market.html The growth rate of the ... device market will remain at double-digit levels throughout the ... as the future of this field. The ...
(Date:9/2/2014)... , Sept. 2, 2014 The Pharmaceutical Care ... benefit managers (PBMs), today filed a lawsuit in ... new Iowa law that restricts ... for the state,s employers and consumers.  ... by severely restricting the use of Maximum Allowable Cost ...
(Date:9/2/2014)... BARCELONA , Spanien und CALGARY, Alberta ... Vorgestellt in der "State of the ... Kardiologenverbandes 2014    Resverlogix Corp. (TSX: RVX) ... of Medical Affairs bei Resverlogix, beim Kongress des europäischen ... Spanien, einen Vortrag gehalten hat. In seinem Vortrag mit ...
Breaking Medicine Technology:Asia - Pacific Minimally Invasive Surgery Spinal Device Market 2Asia - Pacific Minimally Invasive Surgery Spinal Device Market 3Asia - Pacific Minimally Invasive Surgery Spinal Device Market 4Asia - Pacific Minimally Invasive Surgery Spinal Device Market 5Asia - Pacific Minimally Invasive Surgery Spinal Device Market 6Asia - Pacific Minimally Invasive Surgery Spinal Device Market 7Asia - Pacific Minimally Invasive Surgery Spinal Device Market 8Asia - Pacific Minimally Invasive Surgery Spinal Device Market 9Asia - Pacific Minimally Invasive Surgery Spinal Device Market 10Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6
... DIEGO, May 4, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 2011 financial results after the NASDAQ Global Select Market closes ... Arena,s President and Chief Executive Officer, will host a conference ... Pacific Time) to discuss the financial results for the first ...
... ULURU Inc. (NYSE AMEX: ULU) ... with the U.S. Food and Drug Administration to obtain ... containing wound care products represent a growing segment of ... and contributes to new tissue development. Collagen dressings encourage ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 3ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Ergotec Vetriretinal Instrument System. Ultra-fine angled tips (4 mm) with 20 gauge shaft. 25 mm in length. Overall length from rear rotation knob to tip....
Medicine Products: